Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
and Mayo, L.M., "GLP-1 receptor agonists for the treatment of alcohol use disorder," Journal of Clinical Investigation, May 1, 2025, doi: 10.1172/JCI192414 Hendershot, C.S., et al, "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial," JAMA Psychiatry, April 1, 2025, doi: 10.1001/jamapsychiatry.2024.4789 Wang, W., et al, "Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data," Annals of Internal Medicine, Aug
These findings warrant a deeper exploration of the underlying mechanisms and broader implications of GLP-1RA therapy beyond the numerical results
Research indicates potential mechanisms including: Increased dopamine release in the mPOA following MC4R activation Enhanced dopaminergic neuron activity in reward pathways Modulation of dopamine receptor sensitivity in sexual behavior circuits Indirect effects on mesolimbic reward processing Animal studies using microdialysis demonstrated elevated extracellular dopamine levels in the mPOA following PT-141 administration, suggesting dopamine release may mediate some behavioral effects
77% of Vital Pursuit sales are coming from households where no one is using GLP-1 drugs
The GLP-1 works by stimulating the release of insulin when blood sugar levels rise and also slows down the release of glucose from the liver
In another study, published in Clinical Pharmacokinetics , researchers also found that water intake, fasting time and meal timing can affect the amount of the drug that enters the bloodstream
US$ 27.67
US$ 22.19
US$ 26.84
US$ 22.50
